Related Experiment Video
Updated: Apr 19, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
Daniel Morgensztern1, Meghan J Campo, Suzanne E Dahlberg
1*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.
Abstract:
There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.
Insights
Recent advances in non-small-cell lung cancer (NSCLC) include targeted therapies and immunotherapy. Understanding acquired resistance and genomic alterations is key to improving NSCLC treatment outcomes.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Significant progress has been made in understanding non-small-cell lung cancer (NSCLC) biology and treatment.
- Molecularly targeted agents are increasingly available for advanced NSCLC.
- Mechanisms of acquired resistance to tyrosine kinase inhibitors in oncogene-addicted NSCLC are being elucidated.
Purpose of the Study:
- To summarize recent breakthroughs in NSCLC research.
- To highlight advances in cancer genomics, targeted therapies, and immunotherapy for NSCLC.
Main Methods:
- Review of current literature on NSCLC.
- Analysis of data from clinical trials and genomic studies.
- Synthesis of information on targeted agents and immune checkpoint inhibitors.
Main Results:
- Next-generation sequencing has enabled comprehensive study of genomic alterations in lung cancer.
- Early results from immune checkpoint inhibitors show promising outcomes.
- Understanding acquired resistance mechanisms is advancing.
Conclusions:
- Recent advances in NSCLC treatment involve targeted therapies and immunotherapy.
- Genomic insights are crucial for developing personalized NSCLC treatments.
- Further research into resistance mechanisms and novel therapeutic strategies is warranted.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers